A 38-year-old woman with chronic liver disease (Child-Pugh Class B) and portal hypertension is scheduled for emergency drainage of a hepatic abscess under general anesthesia. The anesthesiologist is considering inhalational agents for maintenance. Which agent would be most appropriate, and what is the primary pharmacokinetic concern in this patient?

Explanation

## Inhalational Agents in Hepatic Disease **Key Point:** Sevoflurane is the agent of choice in patients with hepatic dysfunction because it undergoes minimal hepatic metabolism (~3–5%), has low blood-gas solubility (rapid emergence), and does not accumulate in hepatic disease. The primary concern with other volatile agents is hepatic metabolism and potential for hepatotoxicity. ### Hepatic Metabolism of Volatile Anesthetics | Agent | Hepatic Metabolism | Clinical Implication in Liver Disease | |-------|---|---| | **Sevoflurane** | 3–5% | **SAFE — minimal metabolism, rapid elimination** | | Isoflurane | 0.2% | Minimal metabolism BUT slower emergence than sevoflurane | | Desflurane | <0.02% | Minimal metabolism BUT airway irritation, not ideal for induction | | Halothane | 20% | **CONTRAINDICATED — hepatic metabolism, risk of hepatotoxicity** | | Enflurane | 2–8% | Potential fluoride ion accumulation; less commonly used | **High-Yield:** In hepatic disease, the ranking for safety is: 1. **Sevoflurane** (best choice) 2. Isoflurane 3. Desflurane 4. ~~Halothane~~ (contraindicated) ### Why Sevoflurane Is Optimal in Liver Disease 1. **Minimal hepatic metabolism (3–5%)** - Does not depend on hepatic function for elimination - No accumulation in hepatic disease 2. **Rapid emergence** - Low blood-gas solubility (0.65) - Allows quick recovery even if hepatic function is impaired - Predictable pharmacokinetics 3. **No hepatotoxicity risk** - Does not produce hepatotoxic metabolites - Safe even in advanced cirrhosis 4. **Maintains hemodynamics** - Preserves cerebral autoregulation - Less myocardial depression than halothane - Important in portal hypertension with hemodynamic compromise **Clinical Pearl:** Sevoflurane's low solubility (0.65) means it is rapidly eliminated via the lungs, independent of hepatic or renal function. This makes it ideal for patients with organ dysfunction. In contrast, halothane (solubility 2.3) undergoes 20% hepatic metabolism and can produce hepatotoxic metabolites, increasing the risk of postoperative hepatic dysfunction or fulminant hepatic failure. ### Fluoride Ion Concern Sevoflurane is metabolized to inorganic fluoride ions (~3–5% of dose). In normal patients, fluoride levels are well below the nephrotoxic threshold (~50 μmol/L). In hepatic disease, fluoride accumulation is not a concern because: - The metabolism is minimal - Renal excretion is usually adequate - Peak fluoride levels remain safe **Mnemonic:** **"Volatile Agents in Liver Disease: SHED"** - **S**evoflurane — SAFE (minimal metabolism, rapid emergence) - **H**alothane — HAZARDOUS (20% hepatic metabolism, hepatotoxicity) - **E**nflurane — EXTRA caution (2–8% metabolism, fluoride ions) - **D**esflurane — DECENT (minimal metabolism, but airway irritant) ## Management in This Case - **Induction:** Propofol or etomidate (avoid thiopental if possible due to prolonged action) - **Maintenance:** Sevoflurane + N₂O + opioid - **Neuromuscular blockade:** Cisatracurium or rocuronium (avoid atracurium due to Hofmann elimination) - **Monitoring:** Maintain MAP >65 mmHg (portal hypertension risk); watch for coagulopathy - **Emergence:** Expect rapid, predictable emergence due to sevoflurane's low solubility